The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | MASTER subgroup analysis: quadruplet induction, autoSCT & treatment cessation in NDMM patients ≥70
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the results from a subgroup analysis of the Phase II MASTER trial (NCT03224507), which analyzed quadruplet induction, autologous stem cell transplantation (autoSCT) and measurable residual disease (MRD)-guided treatment cessation in patients with newly diagnosed multiple myeloma (NDMM) aged 70 or older. Results demonstrated that while there was a slight difference in the frequency of achieving MRD negativity, there was no difference in safety observed between younger and older patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding.
